Non-melanoma Skin Cancer

Overview

Journal Clin Med (Lond)

Specialty General Medicine

Date 2016 Feb 3

PMID 26833519

Citations 41

Authors

Liezel L Griffin

Faisal Rehman Ali

John T Lear

Affiliations

Soon will be listed here.

Abstract

Non-melanoma skin cancer (NMSC) comprises basal cell carcinoma (BCC) and squamous cell carcinoma, together with a host of rare tumours. NMSC is the commonest malignancy among Caucasians and its incidence continues to rise annually. Exposure to UV radiation initiates approximately 90% of NMSC, causing malignant transformation of keratinocytes and suppression of the inflammatory response. Risk factors include sun exposure and immunosuppression. There are several subtypes of BCC, although histological overlap is common. Surgery has traditionally been regarded as the 'gold-standard' treatment, offering excellent cure rates and cosmetic results. Other treatment modalities include physical destruction (radiotherapy, curettage and cautery, and cryotherapy), chemical destruction (photodynamic therapy and topical 5-flurouracil) and immunomodulatory therapy (topical imiquimod). The recent development of novel hedgehog pathway inhibitors for high-risk BCC (including oral vismodegib and sonidegib) may represent a paradigm shift towards medical management of NMSC.

Citing Articles

Unraveling the controversy: exploring the link between sex hormones and skin cancers through a meta-analysis and systematic review.

Zhao T, Li C, Zhong A, Yun J, Chen J Arch Dermatol Res. 2025; 317(1):292.

PMID: 39825969 DOI: 10.1007/s00403-024-03791-7.

Primary cilia-associated signalling in squamous cell carcinoma of head and neck region.

Putnova I, Putnova B, Hurnik P, Stembirek J, Buchtova M, Koliskova P Front Oncol. 2024; 14:1413255.

PMID: 39234399 PMC: 11372790. DOI: 10.3389/fonc.2024.1413255.

Association between cathepsins and skin cancers: A bidirectional two-sample Mendelian randomization study.

Ma X, Zhuang H, Xu M, Hou F, Xue C Skin Res Technol. 2024; 30(8):e13905.

PMID: 39138831 PMC: 11322223. DOI: 10.1111/srt.13905.

Advanced and Metastatic Non-Melanoma Skin Cancer: Epidemiology, Risk Factors, Clinical Features, and Treatment Options.

Attal Z, Shalata W, Soklakova A, Tourkey L, Shalata S, Abu Saleh O Biomedicines. 2024; 12(7).

PMID: 39062023 PMC: 11274597. DOI: 10.3390/biomedicines12071448.

Effectiveness and Patient Experiences of Rhenium Skin Cancer Therapy for Nonmelanoma Skin Cancer: Interim Results from the EPIC-Skin Study.

Baxi S, Vohra S, Hong A, Mulholland N, Heuschkel M, Dahlhoff G J Nucl Med. 2024; 65(9):1450-1455.

PMID: 39025650 PMC: 11372259. DOI: 10.2967/jnumed.124.267988.

References

Motley R, Kersey P, Lawrence C . Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma. Br J Dermatol. 2002; 146(1):18-25. DOI: 10.1046/j.0007-0963.2001.04615.x. View

Wong C, Strange R, Lear J . Basal cell carcinoma. BMJ. 2003; 327(7418):794-8. PMC: 214105. DOI: 10.1136/bmj.327.7418.794. View

Rubin A, Chen E, Ratner D . Basal-cell carcinoma. N Engl J Med. 2005; 353(21):2262-9. DOI: 10.1056/NEJMra044151. View

Braathen L, Szeimies R, Basset-Seguin N, Bissonnette R, Foley P, Pariser D . Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol. 2006; 56(1):125-43. DOI: 10.1016/j.jaad.2006.06.006. View

Erb P, Ji J, Kump E, Mielgo A, Wernli M . Apoptosis and pathogenesis of melanoma and nonmelanoma skin cancer. Adv Exp Med Biol. 2008; 624:283-95. DOI: 10.1007/978-0-387-77574-6_22. View

Telfer N, Colver G, Morton C . Guidelines for the management of basal cell carcinoma. Br J Dermatol. 2008; 159(1):35-48. DOI: 10.1111/j.1365-2133.2008.08666.x. View

Pleasance E, Cheetham R, Stephens P, McBride D, Humphray S, Greenman C . A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2009; 463(7278):191-6. PMC: 3145108. DOI: 10.1038/nature08658. View

Madan V, Lear J, Szeimies R . Non-melanoma skin cancer. Lancet. 2010; 375(9715):673-85. DOI: 10.1016/S0140-6736(09)61196-X. View

Lomas A, Leonardi-Bee J, Bath-Hextall F . A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012; 166(5):1069-80. DOI: 10.1111/j.1365-2133.2012.10830.x. View

10.

Lear J . Oral hedgehog-pathway inhibitors for basal-cell carcinoma. N Engl J Med. 2012; 366(23):2225-6. DOI: 10.1056/NEJMe1202170. View

11.

Sexton M, Jones D, Maloney M . Histologic pattern analysis of basal cell carcinoma. Study of a series of 1039 consecutive neoplasms. J Am Acad Dermatol. 1990; 23(6 Pt 1):1118-26. DOI: 10.1016/0190-9622(90)70344-h. View

12.

Silverberg M, Leyden W, Warton E, Quesenberry Jr C, Engels E, Asgari M . HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer. J Natl Cancer Inst. 2013; 105(5):350-60. PMC: 3589255. DOI: 10.1093/jnci/djs529. View

13.

Ali F, Lear J . Systemic treatments for basal cell carcinoma (BCC): the advent of dermato-oncology in BCC. Br J Dermatol. 2013; 169(1):53-7. DOI: 10.1111/bjd.12311. View

14.

Kim D, Kim J, Spaunhurst K, Montoya J, Khodosh R, Chandra K . Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol. 2014; 32(8):745-51. DOI: 10.1200/JCO.2013.49.9525. View

15.

Leigh I . Progress in skin cancer: the U.K. experience. Br J Dermatol. 2014; 171(3):443-5. DOI: 10.1111/bjd.13258. View

16.

Migden M, Guminski A, Gutzmer R, Dirix L, Lewis K, Combemale P . Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015; 16(6):716-28. DOI: 10.1016/S1470-2045(15)70100-2. View

17.

Basset-Seguin N, Hauschild A, Grob J, Kunstfeld R, Dreno B, Mortier L . Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015; 16(6):729-36. DOI: 10.1016/S1470-2045(15)70198-1. View

18.

Rowe D, Carroll R, Day Jr C . Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol. 1989; 15(3):315-28. DOI: 10.1111/j.1524-4725.1989.tb03166.x. View

19.

Rowe D, Carroll R, Day Jr C . Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol. 1989; 15(4):424-31. DOI: 10.1111/j.1524-4725.1989.tb03249.x. View